{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:16:03Z","timestamp":1777889763351,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Perit Dial Int"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:sec>\n                    <jats:title>\u2666Background<\/jats:title>\n                    <jats:p>Peginesatide is a novel, synthetic, peptide-based pegylated erythropoiesis-stimulating agent that is designed specifically to stimulate the erythropoietin receptor. The purpose of the present study was to assess, for the first time, the efficacy and safety of peginesatide in chronic kidney disease (CKD) patients receiving peritoneal dialysis (PD) and previously on epoetin treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\u2666Methods<\/jats:title>\n                    <jats:p>In this open-label multicenter study, 59 PD patients with CKD were converted from epoetin (alfa or beta) to once-monthly peginesatide. Doses were titrated to maintain hemoglobin levels between 10 g\/dL and 12 g\/dL during the 25 weeks of the study. The primary endpoint was change from baseline in mean hemoglobin values during the evaluation period (weeks 20 \u2013 25).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\u2666Results<\/jats:title>\n                    <jats:p>The mean hemoglobin value during the evaluation period was 11.3 \u00b1 1.07 g\/dL, and the mean change from baseline was 0.10 \u00b1 1.15 g\/dL (95% confidence limits: \u20130.24, 0.44 g\/dL). During the evaluation period, most patients maintained hemoglobin levels between 10 g\/dL and 12 g\/dL (63.0%) and within \u00b11.0 g\/dL of baseline (60.9%). The median weekly epoetin dose at baseline was 96.0 U\/kg, and the median starting peginesatide dose was 0.047 mg\/kg. Forty-three patients (72.9%) completed the study. Six patients (10.2%) received red blood cell transfusions. The observed adverse event profile was consistent with underlying conditions in the PD patient population. The most common adverse event was peritonitis (20.3%), a complication commonly associated with PD. Four deaths occurred during the study (2 related to septic shock, and 1 each to myocardial ischemia and myasthenia gravis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\u2666Conclusions<\/jats:title>\n                    <jats:p>In this study, once-monthly peginesatide maintained hemoglobin levels in PD patients after conversion from epoetin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3747\/pdi.2012.00224","type":"journal-article","created":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T20:35:08Z","timestamp":1393706108000},"page":"481-489","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis"],"prefix":"10.1177","volume":"35","author":[{"given":"Raja","family":"Zabaneh","sequence":"first","affiliation":[{"name":"Northwest Louisiana Nephrology, Shreveport, Louisiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon D.","family":"Roger","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Gosford Hospital, Gosford, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"El-Shahawy","sequence":"additional","affiliation":[{"name":"University of Southern California, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Roppolo","sequence":"additional","affiliation":[{"name":"Renal Associates of Baton Rouge, Baton Rouge, Louisiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant","family":"Runyan","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Deerfield, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"O'Neil","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Deerfield, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Qiu","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Deerfield, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,7,1]]},"reference":[{"key":"bibr1-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17789-7"},{"key":"bibr2-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60165-2"},{"key":"bibr3-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-12-992"},{"key":"bibr4-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10831210"},{"key":"bibr5-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-13-95"},{"key":"bibr6-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203165"},{"key":"bibr7-pdi.2012.00224","unstructured":"United States, Department of Health and Human Services, Food and Drug Administration (FDA) Affymax and Takeda Announce a National Voluntary Recall of All Lots of Omontys (Peginesatide) Injection [press release]. Silver Spring, MD: FDA; February 23, 2013. [Available online at: http:\/\/www.fda.gov\/Safety\/Recalls\/ucm340893.htm; accessed 6 August 2013]"},{"key":"bibr8-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.06.013"},{"key":"bibr9-pdi.2012.00224","volume-title":"USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.","author":"United States, Department of Health and Human Services, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, US Renal Data System (USRDS).","year":"2011"},{"key":"bibr10-pdi.2012.00224","first-page":"136","volume":"29","author":"Bajo M.","year":"2009","journal-title":"Nefrologia"},{"key":"bibr11-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2002.34925"},{"key":"bibr12-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.06.008"},{"key":"bibr13-pdi.2012.00224","unstructured":"United States, Department of Health and Human Services, National Institutes of Health, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events. Ver. 3.0. Bethesda, MD: CTEP; 2006. [Available online at: http:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcaev3.pdf; accessed 11 June 2011]"},{"key":"bibr14-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh761"},{"key":"bibr15-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00584.x"},{"key":"bibr16-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.08.015"},{"key":"bibr17-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.10.008"},{"key":"bibr18-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.1177\/089686089701700411"},{"key":"bibr19-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10985"},{"key":"bibr20-pdi.2012.00224","unstructured":"United States, Department of Health and Human Services, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, US Renal Data System (USRDS). USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Chapter 1: Incidence, prevalence, patient characteristics, and modalities. Bethesda, MD: USRDS; 2011. [Available online at: http:\/\/www.usrds.org\/2011\/pdf\/v2_ch01_11.pdf; accessed 27 August 2012]"},{"key":"bibr21-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn320"},{"key":"bibr22-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.08.013"},{"key":"bibr23-pdi.2012.00224","volume-title":"Epogen (Epoetin Alfa) Injection, for Intravenous or Subcutaneous Use","author":"Amgen Inc","year":"2010"},{"key":"bibr24-pdi.2012.00224","unstructured":"Hoffmann\u2013La Roche NeoRecormon Multidose 50,000 IU. Lyophilisate and Solvent for Solution for Injection: Epoetin Beta [package leaflet]. Basel, Switzerland: Hoffmann\u2013La Roche; 2011. [Available online at: http:\/\/www.medicines.org.uk\/EMC\/pdfviewer.aspx?isAttachment=true&documentid=11864; accessed 22 October 2011]"},{"key":"bibr25-pdi.2012.00224","volume-title":"Aranesp (Darbepoetin Alfa): Subcutaneous Injection; Intravenous Injection","author":"Amgen Inc.","year":"2011"},{"key":"bibr26-pdi.2012.00224","unstructured":"Hoffmann\u2013La Roche Mircera Product Information. Annex 1: Summary of Product Characteristics. Basel, Switzerland: Hoffmann\u2013La Roche; 2012. [Available online at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000739\/WC500033672.pdf; accessed 16 December 2013]"},{"key":"bibr27-pdi.2012.00224","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074037"}],"container-title":["Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3747\/pdi.2012.00224","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3747\/pdi.2012.00224","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3747\/pdi.2012.00224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:20:37Z","timestamp":1777612837000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3747\/pdi.2012.00224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.3747\/pdi.2012.00224"],"URL":"https:\/\/doi.org\/10.3747\/pdi.2012.00224","relation":{},"ISSN":["0896-8608","1718-4304"],"issn-type":[{"value":"0896-8608","type":"print"},{"value":"1718-4304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}